Glenmark Pharmaceuticals Limited

Equities

GLENMARK

INE935A01035

Pharmaceuticals

Market Closed - NSE India S.E. 08:01:59 2024-03-28 am EDT 5-day change 1st Jan Change
958.4 INR -0.42% Intraday chart for Glenmark Pharmaceuticals Limited +1.24% +12.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited from Glenmark Pharmaceuticals Limited. CI
Nomura Adjusts Glenmark Pharmaceuticals’ Price Target to INR909 From INR841, Keeps at Neutral MT
Transcript : Glenmark Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 16, 2024
Indian shares set to open higher RE
India's Glenmark Pharma posts loss for Q3 as remediation cost weighs RE
Glenmark Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Glenmark Pharma, Pfizer Launch Atopic Dermatitis Oral Treatment in India MT
Indian shares set to open higher ahead of national budget RE
Glenmark Pharmaceuticals Limited Partners with Pfizer to Launch Abrocitinib in India CI
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable MT
India's Glenmark Life Sciences posts Q3 profit rise; strong orderbook ahead, says CEO RE
Glenmark Pharmaceuticals Limited Launches Biosimilar of the Popular Antidiabetic Drug, Liraglutide, for the First Time in India CI
Glenmark Pharmaceuticals Introduces Anti-Diabetic Drug Liraglutide in India MT
Transcript : Glenmark Pharmaceuticals Limited, Q2 2024 Earnings Call, Nov 15, 2023
Glenmark Pharmaceuticals Swings to Loss in Fiscal Q2; Shares Slide 5% MT
India's Glenmark Pharma posts Q2 loss on exceptional legal costs RE
Glenmark Pharmaceuticals Gets US FDA's Final Approval for Generic Anti-Psychotic Drug MT
Glenmark Pharmaceuticals Limited Receives ANDA Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg CI
India's Glenmark Life Sciences posts Q2 profit rise on API boost RE
Glenmark Pharma Launches Diabetes Control Drug in India MT
Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-Morbidities CI
Glenmark Pharmaceuticals Gets USFDA Nod for Apremilast Tablets MT
Glenmark Pharmaceuticals Receives ANDA Approval for Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg CI
Indian Equities End Lower on Profit Booking; IT Tops Laggards MT
Glenmark Pharma Unit Licenses Antibody Portfolio to Astria Therapeutics MT
Chart Glenmark Pharmaceuticals Limited
More charts
Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
962.4 INR
Average target price
923 INR
Spread / Average Target
-4.10%
Consensus

Quarterly revenue - Rate of surprise